- Home
- ADMA vs PRCT Comparison
ADMA vs PRCT Comparison
Compare ADMA & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADMA
- PRCT
- Stock Information
- Founded
- ADMA 2004
- PRCT 2009
- Country
- ADMA United States
- PRCT United States
- Employees
- ADMA N/A
- PRCT N/A
- Industry
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- PRCT Medical Specialities
- Sector
- ADMA Health Care
- PRCT Health Care
- Exchange
- ADMA Nasdaq
- PRCT Nasdaq
- Market Cap
- ADMA 4.1B
- PRCT 4.7B
- IPO Year
- ADMA N/A
- PRCT 2021
- Fundamental
- Price
- ADMA $16.32
- PRCT $82.00
- Analyst Decision
- ADMA Strong Buy
- PRCT Strong Buy
- Analyst Count
- ADMA 4
- PRCT 7
- Target Price
- ADMA $21.25
- PRCT $97.86
- AVG Volume (30 Days)
- ADMA 2.3M
- PRCT 554.2K
- Earning Date
- ADMA 02-26-2025
- PRCT 02-25-2025
- Dividend Yield
- ADMA N/A
- PRCT N/A
- EPS Growth
- ADMA N/A
- PRCT N/A
- EPS
- ADMA 0.28
- PRCT N/A
- Revenue
- ADMA $382,809,000.00
- PRCT $199,843,000.00
- Revenue This Year
- ADMA $67.03
- PRCT $67.07
- Revenue Next Year
- ADMA $14.58
- PRCT $40.64
- P/E Ratio
- ADMA $58.22
- PRCT N/A
- Revenue Growth
- ADMA 63.39
- PRCT 71.71
- 52 Week Low
- ADMA $4.82
- PRCT $44.02
- 52 Week High
- ADMA $23.64
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- ADMA 36.43
- PRCT 41.08
- Support Level
- ADMA $17.82
- PRCT $79.56
- Resistance Level
- ADMA $18.88
- PRCT $89.49
- Average True Range (ATR)
- ADMA 0.84
- PRCT 3.30
- MACD
- ADMA -0.08
- PRCT 0.19
- Stochastic Oscillator
- ADMA 12.01
- PRCT 24.57
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.